Cognition Therapeutics, Inc.
NASDAQ:CGTX
0.47 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cognition Therapeutics, Inc. |
Symbool | CGTX |
Munteenheid | USD |
Prijs | 0.471 |
Beurswaarde | 18,898,611 |
Dividendpercentage | 0% |
52-weken bereik | 0.34 - 2.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Lisa Ricciardi |
Website | https://www.cogrx.com |
An error occurred while fetching data.
Over Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)